Table 1.
Histology of samples and clinical data of patients.
| RSG 0 | RSG 1 | RSG 2 | RSG 3 | Total | |
|---|---|---|---|---|---|
| Samples with >50% tumor used for metabolomics (n = 85) | |||||
| Samples (percent) | 11 (12.9%) | 47 (55.3%) | 23 (27.1%) | 4 (4.7%) | 85 |
| Median Grade Group (range) | 3 (1–5) | 1 (1–5) | 3 (1–5) | 4.5 (3–5) | 2 (1–5) |
| Mean tumor percent (range) | 89.5 (70–100) | 82.3 (60–92.5) | 83.2 (62.5–100) | 88.1 (72.5–97.5) | 83.6 (60–100) |
| Samples with >50% tumor used for transcriptomics (n = 78) | |||||
| Samples (percent) | 10 (12.8%) | 41 (52.3%) | 23 (29.5%) | 4 (5.2%) | 78 |
| Median Grade Group (range) | 2.5 (1–5) | 1 (1–5) | 3 (1–4) | 4.5 (3–5) | 2 (6–10) |
| Mean tumor percent (range) | 87.5 (70–100) | 83.2 (57.5–95) | 83.2 (62.5–100) | 88.1 (72.5–97.5) | 84.0 (57.5–100) |
| Clinical variables of Patients (n = 38) | |||||
| Patients (percent) | 2 (5.3%) | 24 (63.2%) | 10 (26.3%) | 2 (5.3%) | 38 |
| Recurrence, 5 year follow-up (percent) | 0 | 1 (4.2%) | 7 (70.0%) | 1 (50.0%) | 11 (28.9%) |
| Mean age at operation (range) | 58.5 (56–61) | 61.4 (48–69) | 62.1 (48–68) | 68.5 (68–69) | 61.8 (48–69) |
| Median Grade Group (range) | 2 (2) | 2 (1–5) | 3.5 (1–5) | 5 (5) | 3 (1–5) |
| Median pathological stage (range) | T2c (T2c) | T2c (T2a–T3b) | T3a (T2c–T3b) | T3b (T3a–T3b) | T2c (T2a–T3b) |
| Mean preoperative serum PSA (range) | 8.0 (5.2–10.7) | 10.8 (3.7–45.8) | 10.6 (5.2–17.0) | 9.75 (5.6–13.9) | 10.3 (3.7–48.8) |
RSG = reactive stroma grade, PSA = prostate specific antigen.